New NGS-Assay for HRD determination
Detection of mutations in 20 HRR genes and determination of the HRD status
The AmoyDx® HRD Complete Panel is an advanced development of the AmoyDx® HRD Focus Panel, which is already established in many laboratories for determining homologous recombination deficiency (HRD).
In both NGS assays, in addition to the BRCA1/2 mutational status, genomic instability is determined based on 24,000 SNPs, which are evenly distributed throughout the genome. The AmoyDx® HRD Complete Panel can be further used to detect SNVs, InDels and homozygous deletions in 20 genes involved in homologous recombination repair (HRR).
Please find a detailed description of the AmoyDx® HRD Complete Panel here.
This product is for research use only (RUO)
Further topics
Coming soon: AmoyDx® FGFR1-4 NGS Panel
Detection of mutations and fusions in the FGFR1, FGFR2, FGFR3 and FGFR4 genes
IVDR Update October 2022
As a manufacturer and distributor of in vitro diagnostics, our enterprise group with the companies Zytomed Systems GmbH and ZytoVision GmbH attaches great importance to the timely implementation of the requirements of the IVDR (Regulation (EU) 2017/746 of the European Parliament and of the Council of April 5th 2017 on in vitro diagnostic medical devices).
